| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0001836 | Release of cytochrome c from mitochondria | Increases phenotype | PMID:18022205 |
| GO:0003918 | Dna topoisomerase type ii (double strand cut, atp-hydrolyzing) activity | Increases phenotype | PMID:33760604 |
| GO:0004725 | Protein tyrosine phosphatase activity | Increases phenotype | PMID:32493877 |
| GO:0005980 | Glycogen catabolic process | Increases phenotype | PMID:8690080 |
| GO:0006265 | Dna topological change | Increases phenotype | PMID:29272108 |
| GO:0006412 | Translation | Decreases phenotype | PMID:34244458 |
| GO:0006915 | Apoptotic process | Increases phenotype | PMID:11779429; PMID:11783079; PMID:16118208 |
| GO:0006974 | Cellular response to dna damage stimulus | Increases phenotype | PMID:33760604 |
| GO:0008121 | Ubiquinol-cytochrome-c reductase activity | Increases phenotype | PMID:18022205 |
| GO:0008137 | Nadh dehydrogenase (ubiquinone) activity | Decreases phenotype | PMID:18022205 |
| GO:0008219 | Cell death | Increases phenotype | PMID:18022205; PMID:25130544; PMID:8031150; PMID:8653807 |
| GO:0008283 | Cell population proliferation | Decreases phenotype | PMID:19468689; PMID:25130544 |
| GO:0008284 | Positive regulation of cell population proliferation | Decreases phenotype | PMID:7491977 |
| GO:0008285 | Negative regulation of cell population proliferation | Increases phenotype | PMID:30396169 |
| GO:0008654 | Phospholipid biosynthetic process | Increases phenotype | PMID:28552552 |
| GO:0009826 | Unidimensional cell growth | Increases phenotype | PMID:31873818 |
| GO:0010940 | Positive regulation of necrotic cell death | Increases phenotype | PMID:26124276 |
| GO:0010942 | Positive regulation of cell death | Affects phenotype | PMID:7743356 |
| GO:0016049 | Cell growth | Decreases phenotype | PMID:29150332 |
| GO:0017148 | Negative regulation of translation | Increases phenotype | PMID:28241074 |
| GO:0030264 | Nuclear fragmentation involved in apoptotic nuclear change | Increases phenotype | PMID:26124276 |
| GO:0030968 | Endoplasmic reticulum unfolded protein response | Increases phenotype | PMID:23123503 |
| GO:0032464 | Positive regulation of protein homooligomerization | Increases phenotype | PMID:29298433 |
| GO:0032769 | Negative regulation of monooxygenase activity | Increases phenotype | PMID:28726718 |
| GO:0032770 | Positive regulation of monooxygenase activity | Increases phenotype | PMID:28726718 |
| GO:0034063 | Stress granule assembly | Increases phenotype | PMID:34244458 |
| GO:0034440 | Lipid oxidation | Increases phenotype | PMID:106178 |
| GO:0034620 | Cellular response to unfolded protein | Increases phenotype | PMID:34244458 |
| GO:0035794 | Positive regulation of mitochondrial membrane permeability | Increases phenotype | PMID:22226756 |
| GO:0042743 | Hydrogen peroxide metabolic process | Affects phenotype | PMID:31873818 |
| GO:0042919 | Benzoate transport | Decreases phenotype | PMID:8140053 |
| GO:0045429 | Positive regulation of nitric oxide biosynthetic process | Increases phenotype | PMID:37741124 |
| GO:0046466 | Membrane lipid catabolic process | Increases phenotype | PMID:7966357 |
| GO:0046902 | Regulation of mitochondrial membrane permeability | Affects phenotype | PMID:18022205 |
| GO:0050665 | Hydrogen peroxide biosynthetic process | Increases phenotype | PMID:18022205 |
| GO:0051092 | Positive regulation of nf-kappab transcription factor activity | Affects phenotype | PMID:7476933; PMID:7491977 |
| GO:0051881 | Regulation of mitochondrial membrane potential | Affects phenotype | PMID:11779429; PMID:11783079; PMID:16118208 |
| GO:0051882 | Mitochondrial depolarization | Affects phenotype | PMID:18022205 |
| GO:0051901 | Positive regulation of mitochondrial depolarization | Increases phenotype | PMID:22226756 |
| GO:0062029 | Positive regulation of stress granule assembly | Increases phenotype | PMID:28241074 |
| GO:0070992 | Translation initiation complex | Affects phenotype | PMID:34244458 |
| GO:0072593 | Reactive oxygen species metabolic process | Increases phenotype | PMID:18022205; PMID:28214884; PMID:35840659 |
| GO:0140042 | Lipid droplet formation | Increases phenotype | PMID:30547786 |
| GO:1901223 | Negative regulation of nik/nf-kappab signaling | Increases phenotype | PMID:19509257 |
| GO:1901896 | Positive regulation of atpase-coupled calcium transmembrane transporter activity | Decreases phenotype | PMID:28721440 |
| GO:1903407 | Negative regulation of p-type sodium:potassium-exchanging transporter activity | Increases phenotype | PMID:22180340 |
| GO:1903409 | Reactive oxygen species biosynthetic process | Increases phenotype | PMID:29150332 |
| GO:1905538 | Polysome binding | Decreases phenotype | PMID:34244458 |
| GO:1905898 | Positive regulation of response to endoplasmic reticulum stress | Increases phenotype | PMID:30547786 |
| GO:2001272 | Positive regulation of cysteine-type endopeptidase activity involved in execution phase of apoptosis | Increases phenotype | PMID:26124276 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.